Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA‚ÄĘCER) (Study P04736)


Phase 3 Results

Eligibility Criteria

Inclusion Criteria

Men and women at least 18 years old with current clinical manifestation of non-ST-segment-elevation myocardial infarction (heart attack) according to the following three criteria:
- current symptoms of cardiac ischemia (chest pain leading to cardiac ischemia or heart attack)
- either of the following:
- concurrent elevation of troponin I or T, or of creatine kinase - myocardial band (CK-MB) to a level above the upper limit of normal, OR
- concurrent appropriate electrocardiographic evidence
- any one (or more) of the following:
- age >= 55 years
- documented history of prior heart attack or coronary revascularization (eg, angioplasty [PCI], coronary artery replacement [CABG])
- diabetes (documented use of insulin or oral hypoglycemic[s])
- documented history of peripheral arterial disease

Exclusion Criteria

- history of intracranial hemorrhage or of central nervous system (CNS) surgery, tumor, or aneurysm
- any bleeding disorder or abnormality
- sustained severe hypertension or valvular heart disease
- current or recent platelet count <100,000 mm^3
- planned or ongoing treatment with a blood thinning medication
- pregnancy
- any significant medical or physiological condition or abnormality that could put the subject at increased risk or limit the subject's ability to participate for the duration of the study